MHE Talks: Patient Access to Multiple Sclerosis Care with Thomas P. Leist of Jefferson University Hospitals

Previous studies have found no association between vaccination and MS in adults. To evaluate the association between vaccinations and pediatric-onset MS, researchers conducted a retrospective case-control study using data from the Bavarian Association of Statutory Health Insurance Physicians database.

Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

The investigational Bruton’s tyrosine kinase performed well in the phase 3 HERCULES trial.

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.

Researchers say patient-reported disability can be used as a metric in outcomes-based contracts related to the care of multiple sclerosis patients.